Everyone thinks that the epidemic is finally over. Now, domestic scientists have found something to restrain COVID-19, which means that the epidemic has seen hope. Is this a fact? First of all, Stephania Stephania is not the same thing at all. Stephania Stephania is an extract. It is not Stephania Stephania that can inhibit COVID-19, so it cannot be used directly.
Secondly, cepharanthine was thought to be effective in inhibiting COVID-19 as early as two years ago. However, in 2022, research will only be conducted in vitro. When it comes to external disinfection water, alcohol and boiled water, it can kill COVID-19 100%, but it does not mean that it can enter the human body.
Whether Yuanfang can become a real anti-epidemic drug needs to be tested, and it depends on whether it can enter animal experiments, human phase I, II, III clinical trials and marketing approval. There are too many unknowns about whether these links can be successfully listed.
Stemona root is an ancient medicine, which was used to treat leukopenia before. This is a new medicine. Since the emergence of coronary pneumonia, many old drugs have been used in anti-COVID-19 research, but none of them can enter the final stage.
Lately, Stephania has suddenly become popular, so we should be wary of the capital market using relevant information to speculate on stock prices. At present, four companies that use cepharanthine have been approved for listing. Two of these four companies have recently been hyped by capital, and their share prices have started to rise, with a considerable increase.
Although cepharanthine can inhibit COVID-19 replication 15393 times, it is only in vitro research data, and it has not been compared with the listed COVID-19 drugs, and even has not been done in clinical trials, so whether it can really be classified as an anti-COVID-19 drug is full of unknowns.